KRAS and adenocarcinoma: KRAS is mutated in 15-25% of NSCLC, mostly adenocarcinoma and occasionally squamous cell carcinoma [25], and is more frequent in white than in Asian populations (25–50% vs 5–15%, respectively) [26].